Country: Canada
Language: English
Source: Health Canada
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
GENERIC MEDICAL PARTNERS INC
N06DA03
RIVASTIGMINE
1.5MG
CAPSULE
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5MG
ORAL
56
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0140521001; AHFS:
APPROVED
2013-02-22
MED-RIVASTIGMINE (Rivastigmine hydrogen tartrate) _Page 1 of 61_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MED-RIVASTIGMINE Rivastigmine Capsules Capsules, 1.5 mg, 3 mg, 4.5 mg, 6 mg Rivastigmine (as rivastigmine hydrogen tartrate), oral Generic Medical Partners Standard Cholinesterase Inhibitor Generic Medical Partners Inc. 1500 Don Mills Road, Suite 711 Toronto, Ontario M3B 3K4 Date of Initial Authorization: February 22, 2013 Date of Revision: MAR 05, 2024 Submission Control Number: 281869 MED-RIVASTIGMINE (Rivastigmine hydrogen tartrate) _Page 2 of 61_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 03/2024 7 WARNINGS AND PRECAUTIONS, Cardiovascular 03/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................................... 2 TABLE OF CONTENTS ...................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................. 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics ................................................................................................................................. 4 1.2 Geriatrics ................................................................................................................................. 4 2 CONTRAINDICATIONS ......................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ......................................................................................... 5 4.1 DOSING CONSIDERATIONS ........................................................................................................ 5 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ........ Read the complete document